Addendum: A breast cancer stem cell niche supported by juxtacrine signalling from monocytes and macrophages.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed.

1. Tumor-Associated Macrophage in Breast Tumor Microenvironment.International journal of molecular sciences · 2025
   Review
2. Tumor-associated macrophages remodel the suppressive tumor immune microenvironment and targeted therapy for immunotherapy.Journal of experimental & clinical cancer research : CR · 2025
   Review
3. Fate decisions of breast cancer stem cells in cancer progression.Frontiers in oncology · 2022
   Review
4. Breast Cancer Stem Cells.Biomedicines · 2018
   Review
5. Long non-coding RNA TUSC7 acts a molecular sponge for miR-10a and suppresses EMT in hepatocellular carcinoma.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016
   Article

Corrections and comments

• Erratum for
  A breast cancer stem cell niche supported by juxtacrine signalling from monocytes and macrophages.2014

Authors and funding

11 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.